Study of Lumateperone as Adjunctive Therapy in the Treatment of Patients With Major Depressive Disorder

Trial details

Who runs it

Intra-Cellular Therapies, Inc.

Trial code

NCT05850689EU 2023-503836-41-00

Record updated

3 November 2026

Original description

This is a multicenter, randomized, double-blind, placebo-controlled parallel-group, fixed-dose study in patients with a primary diagnosis of MDD according to criteria of the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5) who have an inadequate response to ongoing ADT.Read full original descriptionShow less

A Randomized, Double-Blind, Placebo-controlled Multicenter Study to Assess the Efficacy and Safety of Lumateperone as Adjunctive Therapy in the Treatment of Patients With Major Depressive Disorder

This is a multicenter, randomized, double-blind, placebo-controlled parallel-group, fixed-dose study in patients with a primary diagnosis of MDD according to criteria of the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5) who have an inadequate response to ongoing ADT.

Inclusion: Male or female patients between the ages of 18 and 65 years, inclusive; Meets DSM-5 criteria for MDD (MDD with psychotic features will be acceptable) as confirmed by the Investigator or Sponsor-approved rater using the modified Structured Clinical Interview for DSM-5, Clinical Trials Version (SCID-5-CT) and meets all of the following criteria:; The start of the current major depressive episode (MDE) is at least 12 weeks but not more than 18 months prior to Screening; Has at least moderate severity of illness based on rater-administered MADRS total score ≥ 24 at Screening and at Baseline; Has at least moderate severity of illness based on CGI-S score ≥ 4 at Screening and at Baseline; Has a Quick Inventory of Depressive Symptomatology-Self Report-16 item (QIDS-SR-16) score ≥ 14 at Screening and at Baseline; Has sufficient history and medical record confirmation verifying the ADT and the current MDE is causing clinically significant distress or impairment in social, occupational, or other important areas of functioning; Currently having an inadequate response (less than 50% improvement) to 2 or more ADTs in the current MDE as confirmed by the Investigator using the Antidepressant Treatment Response Questionnaire (ATRQ) and taking at least the minimum effective dose (per package insert) of one of the following antidepressants as monotherapy treatment for at least 6 weeks duration:; citalopram/escitalopram; fluoxetine; paroxetine; sertraline; duloxetine; levomilnacipran/milnacipran (if locally approved for MDD); venlafaxine/desvenlafaxine; bupropion; vilazodone; vortioxetine.

Exclusion: Within 6 months of Screening, has a confirmed DSM-5 psychiatric diagnosis other than MDD including:; Anxiety disorders such as Panic Disorder or Generalized Anxiety Disorder; Obsessive-compulsive Disorder; Posttraumatic Stress Disorder as primary diagnoses. Note: Anxiety symptoms may be allowed if secondary to MDD, provided these symptoms do not require concurrent treatment; Eating disorder; Substance use disorders (excluding nicotine); Personality disorder of sufficient severity to have a major impact on the patient's psychiatric status; Within 12 months of Screening, has had any other psychiatric condition (other than MDD) that has been the main focus of treatment; In the opinion of the Investigator, the patient has a significant risk for suicidal behavior during participation in the study or:; At Screening, the patient scores "yes" on Suicidal Ideation Items 4 or 5 of the Columbia-Suicide Severity Rating Scale (C-SSRS) within 6 months prior to Screening, or at Baseline, the patient scores "yes" on Suicidal Ideation Items 4 or 5 since the Screening Visit; At Screening, the patient has had 1 or more suicide attempts within 2 years prior to Screening; At Screening or Baseline, the patient scores ≥ 5 on MADRS Item 10 (Suicidal Thoughts), or; The patient is considered to be in imminent danger to him/herself or others; Within the patient's lifetime, has a confirmed DSM-5 psychiatric diagnosis other than MDD, including:; Schizophrenia, Schizoaffective Disorder, Schizophreniform Disorder or other psychotic disorder; Bipolar Disorder; The patient has a first MDE at age 60 years or older; The patient experiences a ≥ 25% decrease in the MADRS total score between Screening and Baseline; The patient experiences a ≥ 25% decrease in the QIDS-SR-16 total score between Screening and Baseline.

ClinicalTrials.gov NCT05850689 · EU CTIS 2023-503836-41-00